TY - JOUR
T1 - Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy
AU - Yi, Min
AU - Cormier, Janice N.
AU - Xing, Yan
AU - Giordano, Sharon Hermes
AU - Chai, Christy
AU - Meric-Bernstam, Funda
AU - Vlastos, Georges
AU - Kuerer, Henry M.
AU - Mirza, Nadeem Q.
AU - Buchholz, Thomas A.
AU - Hunt, Kelly K.
N1 - Funding Information:
ACKNOWLEDGMENT The authors wish to acknowledge Walter J. Pagel, Department of Scientific Publications, The University of Texas MD Anderson Cancer Center, for editorial assistance. Supported in part by the National Cancer Institute through Cancer Center Support Grant, CA016672 to MD Anderson.
PY - 2013/5
Y1 - 2013/5
N2 - Background: Our purpose was to examine the incidence and impact on survival of other primary malignancies (OPM) outside of the breast in breast cancer patients and to identify risk factors associated with OPM. Methods: Patients with stage 0-III breast cancer treated with breast conserving therapy at our center from 1979 to 2007 were included. Risk factors were compared between patients with/without OPM. Logistic regression was used to identify factors that were associated with OPM. Standardized incidence ratios (SIRs) were calculated. Results: Among 4,198 patients in this study, 276 (6.6 %) developed an OPM after breast cancer treatment. Patients with OPM were older and had a higher proportion of stage 0/I disease and contralateral breast cancer compared with those without OPM. In a multivariate analysis, older patients, those with contralateral breast cancer, and those who did not receive chemotherapy or hormone therapy were more likely to develop OPM after breast cancer. Patients without OPM had better overall survival. The SIR for all OPM sites combined after a first primary breast cancer was 2.91 (95 % confidence interval: 2.57-3.24). Significantly elevated risks were seen for numerous cancer sites, with SIRs ranging from 1.84 for lung cancer to 5.69 for ovarian cancer. Conclusions: Our study shows that breast cancer patients have an increased risk of developing OPM over the general population. The use of systemic therapy was not associated with increased risk of OPM. In addition to screening for a contralateral breast cancer and recurrences, breast cancer survivors should undergo screening for other malignancies.
AB - Background: Our purpose was to examine the incidence and impact on survival of other primary malignancies (OPM) outside of the breast in breast cancer patients and to identify risk factors associated with OPM. Methods: Patients with stage 0-III breast cancer treated with breast conserving therapy at our center from 1979 to 2007 were included. Risk factors were compared between patients with/without OPM. Logistic regression was used to identify factors that were associated with OPM. Standardized incidence ratios (SIRs) were calculated. Results: Among 4,198 patients in this study, 276 (6.6 %) developed an OPM after breast cancer treatment. Patients with OPM were older and had a higher proportion of stage 0/I disease and contralateral breast cancer compared with those without OPM. In a multivariate analysis, older patients, those with contralateral breast cancer, and those who did not receive chemotherapy or hormone therapy were more likely to develop OPM after breast cancer. Patients without OPM had better overall survival. The SIR for all OPM sites combined after a first primary breast cancer was 2.91 (95 % confidence interval: 2.57-3.24). Significantly elevated risks were seen for numerous cancer sites, with SIRs ranging from 1.84 for lung cancer to 5.69 for ovarian cancer. Conclusions: Our study shows that breast cancer patients have an increased risk of developing OPM over the general population. The use of systemic therapy was not associated with increased risk of OPM. In addition to screening for a contralateral breast cancer and recurrences, breast cancer survivors should undergo screening for other malignancies.
UR - http://www.scopus.com/inward/record.url?scp=84880073274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880073274&partnerID=8YFLogxK
U2 - 10.1245/s10434-012-2774-8
DO - 10.1245/s10434-012-2774-8
M3 - Article
C2 - 23224829
AN - SCOPUS:84880073274
SN - 1068-9265
VL - 20
SP - 1514
EP - 1521
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 5
ER -